
Natco Pharma Ltd. — Investor Relations & Filings
Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Disclosure under SEBI Takeover Regulations | 2026-04-29 | English | |
| Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | |
| Trading Window | 2026-03-31 | English | |
| Shareholders meeting | 2026-03-25 | English | |
| Outcome of Board Meeting | 2026-03-24 | English | |
| Press Release | 2026-03-20 | English |
Browse filings by year
17 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 42187393 | Disclosure under SEBI Takeover Regulations | 2026-04-29 | English | ||
| 42174118 | Certificate under SEBI (Depositories and Participants) Regulations, 2018 | 2026-04-09 | English | ||
| 42190499 | Trading Window | 2026-03-31 | English | ||
| 42183610 | Shareholders meeting | 2026-03-25 | English | ||
| 42194221 | Outcome of Board Meeting | 2026-03-24 | English | ||
| 42220287 | Press Release | 2026-03-20 | English | ||
| 43858767 | Board Meeting — Board Meeting Intimation | 2026-03-18 | English | ||
| 43858780 | Board Meeting — Other business matters | 2026-03-18 | English | ||
| 42197773 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-03-06 | English | ||
| 42178518 | Press Release | 2026-03-03 | English | ||
| 42178073 | News Verification | 2026-02-25 | English | ||
| 42195120 | Copy of Newspaper Publication | 2026-02-21 | English | ||
| 42201901 | Shareholders meeting | 2026-02-20 | English | ||
| 42175436 | Analysts/Institutional Investor Meet/Con. Call Updates | 2026-02-18 | English | ||
| 42219592 | Press Release | 2026-02-14 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BIOMM SA
Develops and manufactures biopharmaceuticals and biosimilar…
|
— | BR | Manufacturing |
|
BiomX Inc.
Clinical-stage company developing phage therapies to target…
|
PHGE | US | Manufacturing |
|
BIONEERCORPORATION
Develops and manufactures molecular biology products for re…
|
064550 | KR | Manufacturing |
|
BioNTech SE
Biotechnology company developing immunotherapies for cancer…
|
BNTX | DE | Manufacturing |
|
BioNxt Solutions Inc.
Clinical-stage developer of next-generation drug formulatio…
|
BNXT | CA | Manufacturing |
|
Biophage Pharma Inc.
Developing innovative phage-based therapies for antibiotic-…
|
BIPMF | CA | Manufacturing |
|
BioPorto
An in vitro diagnostics company specializing in biomarkers …
|
BIOPOR | DK | Manufacturing |
|
BIO-RAD LABORATORIES, INC.
Develops and manufactures products for life science and cli…
|
BIO | US | Manufacturing |
|
Biosergen AB
Develops drugs to treat severe and resistant invasive funga…
|
BIOSGN | SE | Manufacturing |
|
Biosino Bio-Technology and Science Incorporation
Major high-tech manufacturer of in-vitro diagnostic (IVD) p…
|
8247 | HK | Manufacturing |
Natco Pharma Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/62741/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=62741 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=62741 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=62741 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 62741}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Natco Pharma Ltd. (id: 62741)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.